(Total Views: 467)
Posted On: 05/17/2024 8:08:26 AM
Post# of 148870
Is it possible to create a long acting version of leronlimab not only in HIV but cancer? What if leronlimab is almost treated like a checkpoint inhibitor?
Long acting version of cancer? Seems like this is what they are talking about during the ABSCI presentation with 301. Shawn specifically talks about an area that has never been explored and there is nobody exploring this area which significantly extends IP for 301.
I know 301 is in house but I believe this is the long acting version of leronlimab and cancer is being explored. He said they will be excited to announce the partnerships by this year with I’m assuming MRK.
There is almost no public information on the actual 301 maybe someone can speak to if this is even on anyone’s radar.
It appears the MOA is different so that’s the only issue here, OHM I’m assuming because the mechanism of action for leronlimab is different from 301 it’s fair to say not the same drug? Even if we make leronlimab long acting it does not change the MOA.
Long acting version of cancer? Seems like this is what they are talking about during the ABSCI presentation with 301. Shawn specifically talks about an area that has never been explored and there is nobody exploring this area which significantly extends IP for 301.
I know 301 is in house but I believe this is the long acting version of leronlimab and cancer is being explored. He said they will be excited to announce the partnerships by this year with I’m assuming MRK.
There is almost no public information on the actual 301 maybe someone can speak to if this is even on anyone’s radar.
It appears the MOA is different so that’s the only issue here, OHM I’m assuming because the mechanism of action for leronlimab is different from 301 it’s fair to say not the same drug? Even if we make leronlimab long acting it does not change the MOA.
(4)
(0)Scroll down for more posts ▼
